$0.13
-0.00(-3.42%)
Mkt Cap $8M
$0.13
$1.22
52-Week Range
At a Glance
AI-generatedBioAtla’s FY2025 performance featured narrowed year-over-year operating and net losses, paired with ongoing liquidity and clinical development cost pressures.
8-K
BioAtla, Inc. has filed a certificate of merger to effect a reverse stock split, consolidating every 50 shares of its common stock into one share, with the merger becoming effective on April 6, 2026.$8M
Market Cap
—
Revenue
-$65M
Net Income
Employees61
Fundamentals
How The Business Makes Money
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001826892
ISINUS09077B1044
CUSIP09077B104
Phone858 558 0708
Address11085 Torreyana Road, San Diego, CA, 92121, US
SEC EDGAR